Celladon Corporation and SIRO Clinpharm Announce Presentation at "Statisticians in the Pharmaceutical Industry International Conference"

MUMBAI, India, May 10, 2013 /PRNewswire/ --

-Analysis of Recurrent Heart Failure Hospitalizations in Presence of Informative Censoring - Application of Joint Frailty Model-

Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced today that it will present analysis methods for the MYDICAR development program at an upcoming Conference.

The conference "Statisticians in the Pharmaceutical Industry International Conference" is being held in Glasgow, UK, on 12-15 May, 2013

"Analysis of Recurrent Heart Failure Hospitalizations in Presence of Informative Censoring" - Application of Joint Frailty Model by Alex Yaroshinsky (Celladon Corporation); Ladislav Pecen (SIRO Clinpharm); and Alena Cernikova (SIRO Clinpharm)

"This conference presentation represents additional recognition of Celladon's innovative approach to the MYDICAR development program, and has many benefits over traditional analysis methods including reduced sample size relative to other heart failure trials," said Krisztina Zsebo Ph.D., President and CEO of Celladon Corp. "It is the first time the U.S Food and Drug Administration has accepted the use of this statistical analysis method as part of a primary endpoint in a clinical trial for the treatment of heart failure," continued Dr. Zsebo.

"SIRO has been in the clinical research space for close to two decades, and one thing that separates us from competition is our ability to continuously innovate. Delivering 'solutions simplified' by partnering with our clients is what we are all about," said Priya Pawar, Global Head, Business Development, SIRO Clinpharm.

About SIRO Clinpharm:

SIRO Clinpharm, winner of Frost & Sullivan 'Clinical Research Organization of the Year' India Healthcare Award 2012 & 2011, is a drug development solutions provider to the global healthcare industry. Our subject expertise gives us an edge in clinical trial management, clinical data management, medical writing, biostatistics and statistical programming pharmacovigilance and clinical trial supplies management. We offer flexible business models across service verticals based on client needs.

Visit us at http://www.siroclinpharm.com.

SOURCE SIRO Clinpharm